Biocryst Pharma Inc (BCRX) |
|
3.945 -0.055 (-1.38%)
|
08-07 14:55 |
|
Open: |
4 |
Pre. Close: |
4 |
|
High:
|
4.03 |
Low:
|
3.81 |
|
Volume:
|
5,248,021 |
Market Cap:
|
696M |
|
|
|
|
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.145 - 4.178 |
4.178 - 4.201 |
|
Low:
|
3.793 - 3.829 |
3.829 - 3.853 |
|
Close:
|
3.952 - 4.009 |
4.009 - 4.047 |
|
Technical analysis |
as of: 2020-08-07 2:24:21 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 6.05  One year: 7.04 |
| Support: |
Support1: 3.81 Support2: 3.17 |
| Resistance: |
Resistance1: 5.18 Resistance2: 6.03 |
| Pivot: |
4.40 |
| Moving Average: |
MA(5): 4.14 MA(20): 4.57
MA(100): 3.99  MA(250): 3.24 |
| MACD: |
MACD(12,26): -0.20 Signal(9): -0.12 |
| Stochastic oscillator: |
%K(14,3): 9.83 %D(3): 14.32 |
| RSI: |
RSI(14): 34.68 |
| 52-week: |
High: 6.29 Low: 1.38 Change(%): 46.4 |
| Average Vol(K): |
3-Month: 772356 10-Days: 677899 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.BCRX has closed above bottom band by 10.7%. Bollinger Bands are 17.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Fri, 07 Aug 2020
BioCryst Pharmaceuticals (BCRX) Q2 2020 Earnings Call Transcript - Nasdaq
Thu, 06 Aug 2020
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2020 Results - Earnings Call Transcript - Seeking Alpha
Thu, 06 Aug 2020
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Thu, 06 Aug 2020
BioCryst: 2Q Earnings Snapshot - SFGate
Thu, 06 Aug 2020
BioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key Milestones - GlobeNewswire
Wed, 05 Aug 2020
BioCryst Pharmaceuticals, Inc. (BCRX) Seems To Be Turning Some Investors Off - Invest Million
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: Nasdaq Global Select |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
176 |
| Shares Float (M) |
135 |
|
% Held by Insiders
|
0.95 |
|
% Held by Institutions
|
90.20 |
|
Shares Short (K)
|
32,100 |
|
Shares Short P. Month (K)
|
18,430 |
Stock Financials |
|
EPS
|
-0.912 |
|
EPS Est This Year
|
-0.750 |
|
EPS Est Next Year
|
-0.780 |
|
Book Value (p.s.)
|
0.020 |
|
Profit Margin
|
-241.66 |
|
Operating Margin
|
-232.57 |
|
Return on Assets (ttm)
|
-49.8 |
|
Return on Equity (ttm)
|
-882.8 |
|
Qtrly Rev. Growth
|
-18.1 |
|
Gross Profit (p.s.)
|
-0.353 |
|
Sales Per Share
|
0.271 |
|
EBITDA (p.s.)
|
-0.626 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-86 |
|
Levered Free Cash Flow (M)
|
-47 |
Stock Valuations |
|
PE Ratio
|
-4.25 |
|
PEG Ratio
|
|
|
Price to Book value
|
194.00 |
|
Price to Sales
|
14.33 |
|
Price to Cash Flow
|
-7.97 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
